[Experimental study of the antibacterial action of levomycatin in a 40% solution of hexamethylenetetramine]. / Eksperimental'noe izuchenie protivobakterial'nogo deistviia levomitsetina v 40% rastvore geksametilentetramina

Antimicrobial and chemotherapeutic activity of 2 per cent solution of levomycetin in 40 per cent solution of hexamethylentetramine was studied. The preparation was proposed as a new extemporal pharmaceutical form of levomycetin for intravenous administration. It was shown that the bacteriostatic activity of levomycetin in the above pharmaceutical form against microbial cultures sensitive to the antibiotic did not differ from that of levomycetin in the form of an aqueous solution. However, the bactericidal effect of the preparation appeared to be higher as compared to that of the levomycetin aqueous solution, which is explained by the synergistic effect of hexamethylentetramine and levomycetin. The chemotherapeutic effect of the preparation tested on albino mice with experimental infection caused by Coli bacteria was more pronounced than the effect of levomycetin sodium succinate.

[Study of the pharmacological properties and safety of a solution of levomycetin in hexamethylene tetramine for intravenous administration]. / Izuchenie farmakologicheskikh svoistv i bezvrednosti rastvora levomitsetina v geksametilentetramine dlia vnutrivennogo vvedeniia

Pharmacological properties of 2 per cent levomycetin solution in 40 percent hexamethylentetramine solution, as a new pharmaceutical form of levomycetin for intravenous administration prepared at drug-stores were studied. The maximum tolerating doses of the drug for mice, rabbits, and dogs were 26-47 times higher than the therapeutic ones with respect to the content of levomycetin and hexamethylentetramine. No increase in the toxicity of levomycetin and hexamethylentetramine in the preparation was observed. The drug in the doses 16 times higher than the therapeutic ones by the content of levomycetin did not almost change the arterial pressure and the drug in the doses 3.7 times higher than the therapeutic ones did not affect the blood coagulation either in acute experiments, or on its prolong intravenous infusion. Repeated administrations of the drug to rats and rabbits for 15-18 days in doses 3.7-4.8 times higher than the therapeutic ones by the content of levomycetin were innocuous for the animals. Absorption, circulation in the blood, distribution in the tissues and excretion with the urine of levomycetin used in the above pharmaceutical form did not differ from circulation of the antibiotic on its intravenous and oral administration. The drug is recommended for use in medical practice.